Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes

Glucuronidation via UDP-glucuronosyltransferase (UGT) is an increasingly important clearance pathway. In this study intrinsic clearance (CLint) values for buprenorphine, carvedilol, codeine, diclofenac, gemfibrozil, ketoprofen, midazolam, naloxone, raloxifene, and zidovudine were determined in pooled human liver microsomes using the substrate depletion approach. The in vitro clearance data indicated a varying contribution of glucuronidation to the clearance of the compounds studied, ranging from 6 to 79% for midazolam and gemfibrozil, respectively. The CLint was ob tained using either individual or combined cofactors for cytochrome P450 (P450) and UGT enzymes with alamethicin activation and in the presence and absence of 2% bovine serum albumin (BSA). In the presence of combined P450 and UGT cofactors, CLint ranged from 2.8 to 688 μl/min/mg for zidovudine and buprenorphine, respectively; the clearance was approximately equal to the sum of the CLint values obtained in the presence of individual cofactors. The unbound intrinsic clearance (CLint, u) was scaled to provide an in vivo predicted CLint; the data obtained in the presence of combined cofactors resulted in 5-fold underprediction on average. Addition of 2% BSA to the incubation with both P450 and UGT cofactors reduced the bias in the clearance prediction, with 8 of 10 compounds predicted within 2-fold of in vivo values with the exception of raloxifene and gemfibrozil. The current study indicates the applicability of combined cofactor conditions in the assessment of clearance for compounds with a differential contribution of P450 and UGT enzymes to their elimination. In addition, improved predictability of microsomal data is observed in the presence of BSA, in particular for UGT2B7 substrates.

[1]  Amin Rostami-Hodjegan,et al.  Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.

[2]  R. Austin,et al.  A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES , 2005, Drug Metabolism and Disposition.

[3]  C. Guillemette,et al.  Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. , 2005, Pharmacogenetics and genomics.

[4]  R. Foti,et al.  ALTERED AZT (3′-AZIDO-3′-DEOXYTHYMIDINE) GLUCURONIDATION KINETICS IN LIVER MICROSOMES AS AN EXPLANATION FOR UNDERPREDICTION OF IN VIVO CLEARANCE: COMPARISON TO HEPATOCYTES AND EFFECT OF INCUBATION ENVIRONMENT , 2005, Drug Metabolism and Disposition.

[5]  J Brian Houston,et al.  Evaluation of Cryopreserved Human Hepatocytes as an Alternative in Vitro System to Microsomes for the Prediction of Metabolic Clearance , 2007, Drug Metabolism and Disposition.

[6]  P. Maurel,et al.  Contribution of the N-Glucuronidation Pathway to the Overall in Vitro Metabolic Clearance of Midazolam in Humans , 2008, Drug Metabolism and Disposition.

[7]  Barry C. Jones,et al.  DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS , 2004, Drug Metabolism and Disposition.

[8]  R. Obach,et al.  The prediction of human clearance from hepatic microsomal metabolism data. , 2001, Current opinion in drug discovery & development.

[9]  J Brian Houston,et al.  In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. , 2006, Biochemical pharmacology.

[10]  Lewis B. Sheiner,et al.  Some suggestions for measuring predictive performance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[11]  A. Galetin,et al.  Drug Lipophilicity and Microsomal Protein Concentration as Determinants in the Prediction of the Fraction Unbound in Microsomal Incubations , 2008, Drug Metabolism and Disposition.

[12]  D. Rock,et al.  CYP2C9 Inhibition: Impact of Probe Selection and Pharmacogenetics on in Vitro Inhibition Profiles , 2006, Drug Metabolism and Disposition.

[13]  J. Houston,et al.  Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. , 1999, British journal of clinical pharmacology.

[14]  J B Houston,et al.  Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.

[15]  Andrew Rowland,et al.  The “Albumin Effect” and Drug Glucuronidation: Bovine Serum Albumin and Fatty Acid-Free Human Serum Albumin Enhance the Glucuronidation of UDP-Glucuronosyltransferase (UGT) 1A9 Substrates but Not UGT1A1 and UGT1A6 Activities , 2008, Drug Metabolism and Disposition.

[16]  Hannah M Jones,et al.  SUBSTRATE DEPLETION APPROACH FOR DETERMINING IN VITRO METABOLIC CLEARANCE: TIME DEPENDENCIES IN HEPATOCYTE AND MICROSOMAL INCUBATIONS , 2004, Drug Metabolism and Disposition.

[17]  A. D. Rodrigues,et al.  GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS , 2006, Drug Metabolism and Disposition.

[18]  L. Benet,et al.  Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? , 1992, Drug metabolism reviews.

[19]  K. Knights,et al.  The “Albumin Effect” and in Vitro-in Vivo Extrapolation: Sequestration of Long-Chain Unsaturated Fatty Acids Enhances Phenytoin Hydroxylation by Human Liver Microsomal and Recombinant Cytochrome P450 2C9 , 2008, Drug Metabolism and Disposition.

[20]  P. Marquet,et al.  IN VITRO METABOLISM STUDY OF BUPRENORPHINE: EVIDENCE FOR NEW METABOLIC PATHWAYS , 2005, Drug Metabolism and Disposition.

[21]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[22]  Kiyomi Ito,et al.  Prediction of Human Drug Clearance from in Vitro and Preclinical Data Using Physiologically Based and Empirical Approaches , 2004, Pharmaceutical Research.

[23]  J. Miners,et al.  Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. , 2004, Annual review of pharmacology and toxicology.

[24]  S. Liao,et al.  Pharmacokinetics and bioavailability of zidovudine in humans. , 1988, The American journal of medicine.

[25]  D J Rance,et al.  The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.

[26]  Tony K L Kiang,et al.  UDP-glucuronosyltransferases and clinical drug-drug interactions. , 2005, Pharmacology & therapeutics.

[27]  J. Houston,et al.  Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. , 1987, Drug metabolism and disposition: the biological fate of chemicals.

[28]  J. Miners,et al.  In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. , 2002, British journal of clinical pharmacology.

[29]  J B Houston,et al.  Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[30]  B. Ring,et al.  Predictions of the In Vivo Clearance of Drugs from Rate of Loss Using Human Liver Microsomes for Phase I and Phase II Biotransformations , 2006, Pharmaceutical Research.

[31]  John C Lipscomb,et al.  Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. , 2007, Current drug metabolism.

[32]  M. Jamei,et al.  Misuse of the Well-Stirred Model of Hepatic Drug Clearance , 2007, Drug Metabolism and Disposition.

[33]  A. Nitenberg,et al.  Reversibility by dipyridamole of thallium-201 myocardial scan defects in patients with sarcoidosis. , 1988, The American journal of medicine.

[34]  T. Baillie,et al.  Extrapolation of Diclofenac Clearance from in Vitro Microsomal Metabolism Data: Role of Acyl Glucuronidation and Sequential Oxidative Metabolism of the Acyl Glucuronide , 2002, Journal of Pharmacology and Experimental Therapeutics.

[35]  S. Wrighton,et al.  In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[36]  B. Ring,et al.  The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[37]  B. Burchell,et al.  In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. , 2002, The Journal of pharmacology and experimental therapeutics.

[38]  Andrew Rowland,et al.  Binding of Inhibitory Fatty Acids Is Responsible for the Enhancement of UDP-Glucuronosyltransferase 2B7 Activity by Albumin: Implications for in Vitro-in Vivo Extrapolation , 2007, Journal of Pharmacology and Experimental Therapeutics.